Food and Drug Administration Sanitary Inspection (FDA) supported the introduction of the Aduhelm product, which was developed by Biogen (Nasdaq: BIIB). Aduhelm - 1st for about 20 years approved product, slowing down?? cognitive decline in people with Alzheimer's disease. Biotech shares up 38% in one day.
The regulator reported, that will continue to follow the products, when it goes on sale. FDA Supported the Introduction of Medicines, but Biogen is obliged to conduct another study in a clinical setting.
The price of one injection of Aduhelm will be 4312 $, and the annual healing will cost 56 thousand. The head of Biogen called the cost fair and also said, that in subsequent 4 she won't grow.
Some experts were incredulous about the new development of Biogen. “We need another study, to establish the productivity of the product. Unfortunately, The FDA has approved the drug for marketing until the last review.", - emphasized the doctor Jason Karlavish, one of the specialized professionals.
According to Karlavish, Aduhelm wrong product, which is to be hoped for. The doctor informs, that a huge number of promising pharmaceuticals for Alzheimer's disease are currently in development.
Alzheimer's disease is the most common type of dementia, in which the brain ceases to perform its functions properly. The disease causes memory problems, thinking and behavior. There are no drugs for today, that could completely stop the action of Alzheimer's disease on the brain.
According to the World Health Organization, in 2019 Alzheimer's disease ranked seventh on the list of the most common causes of death. Alzheimer's disease is not among the top 10 causes of death in low-income and lower middle-income countries. In upper-middle-income countries, the disease ranked eighth, and in high-income countries, the second. In the latter group of countries, deaths from Alzheimer's disease for 20 has grown several times over the years 814 thousand people in 2019 year.
